Neuronetics, Inc. (STIM) Stock Price & Analysis
Neuronetics, Inc. (STIM) rose 0.40% to USD 1.25 as of June 10, 2026 at 17:40 UTC, according to Nexqual real-time market data.
STIM last closed at USD 1.24; the session ranged USD 1.23–1.3 on volume of 237,325 shares. Market capitalization is $86.64M, with a 52-week range of USD 0.8–4.85 (NGM). Source: Nexqual, June 10, 2026 at 17:40 UTC.
Key Statistics (as of June 10, 2026 at 17:40 UTC)
| Price | USD 1.25 |
|---|---|
| Change | ▲ 0.40% (up) |
| Previous Close | USD 1.24 |
| Open | USD 1.25 |
| Day Range | USD 1.23 – 1.3 |
| 52-Week Range | USD 0.8 – 4.85 |
| Volume | 237,325 shares |
| Market Cap | $86.64M |
| Exchange | NGM |
Technical Analysis (STIM)
Nexqual's technical model rates STIM "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of June 10, 2026 at 17:40 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.09 (neutral) |
| vs SMA50 | Below (USD 1.5) |
| MACD | -0.06 (negative) |
Analyst Ratings (STIM)
Wall Street analysts rate STIM "None" based on 3 analysts, with a mean price target of USD 4.33 (range USD 3–7), per Nexqual as of June 10, 2026 at 17:40 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 4.33 |
| High Target | USD 7 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (STIM)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD -0.12 |
| Revenue Estimate | $40.49M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.15 vs est -0.17 ▲ beat |
| 2025-12-31 | USD -0.1 vs est -0.11 ▲ beat |
| 2025-09-30 | USD -0.13 vs est -0.12 ▼ miss |
| 2025-06-30 | USD -0.15 vs est -0.08 ▼ miss |
Source: Nexqual, June 10, 2026 at 17:40 UTC.
Financials & Fundamentals (STIM)
| Total Revenue | $151.64M |
|---|---|
| Revenue Growth (YoY) | +7.80% |
| Gross Margin | +48.22% |
| Operating Margin | -26.11% |
| Profit Margin | -24.48% |
| ROE | -131.56% |
| Debt / Equity | 500.52 |
| Current Ratio | 1.67 |
| Total Cash | $13.21M |
| Total Debt | $85.39M |
| Free Cash Flow | $-4.58M |
Source: Nexqual, June 10, 2026 at 17:40 UTC.
Financial Health Score (STIM)
Nexqual rates Neuronetics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 17:40 UTC.
| Growth | Strong — Revenue +100% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 48%, operating -26% |
| Balance Sheet | Critical — $13M cash vs $85M debt |
| Cash Flow | Weak — FCF negative: -$5M, burning cash |
| Efficiency | Critical — ROE -132%, ROA -13.6% |
Ownership (STIM)
| Insider Ownership | +32.46% |
|---|---|
| Institutional Ownership | +59.86% |
| Shares Outstanding | 69.59M |
| Float | 30.67M |
| Short % of Float | +28.76% |
Source: Nexqual, June 10, 2026 at 17:40 UTC.
Leadership (STIM)
Neuronetics, Inc. is led by Daniel L. Reuvers (age 62), CEO, President & Director, per Nexqual as of June 10, 2026 at 17:40 UTC.
| CEO, President & Director | Daniel L. Reuvers (age 62) |
|---|---|
| SVP & Chief Technology Officer | Cory S. Anderson |
| Senior VP & Chief Marketing Officer | Lisa Metzner-Rosas |
| Senior Vice President of Sales | Robert Greene |
Major Backers & Investors (STIM)
Notable institutional backers of Neuronetics, Inc. include Madryn Asset Management, LP, UBS Group AG, Balyasny Asset Management LP, according to Nexqual as of June 10, 2026 at 17:40 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Madryn Asset Management, LP | 26.55% |
| UBS Group AG | 4.13% |
| Balyasny Asset Management LP | 3.94% |
| Lane Generational LLC | 2.55% |
| FourWorld Capital Management, LLC | 2.14% |
| Masters Capital Management, LLC | 1.44% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.12% |
| BlackRock | 5.08% |
| Geode Capital | 1.38% |
| State Street | 1.21% |
Source: Nexqual, June 10, 2026 at 17:40 UTC.
From Neuronetics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally.
- The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
- Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.
- The company sells its products through its sales and customer support team to psychiatrists.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VRCA | Verrica Pharmaceuticals Inc. | USD 6.34 | ▲ 5.84% |
| STRO | Sutro Biopharma, Inc. | USD 26.28 | ▲ 3.42% |
| SIBN | SI-BONE, Inc. | USD 15.6 | ▲ 4.21% |
| SYBX | Synlogic, Inc. | USD 0.6 | ▼ 17.81% |
| EVLO | Evelo Biosciences, Inc. | USD 0 | ▲ 200% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 17:40 UTC. This page is informational and not investment advice.